Accuity vs Evidently
Two Revenue Integrity & Pre-Bill Review vendors, side by side. Facts from public sources; judgments are ours.
At a glance
Derived from public facts · a rough scale, not a ranking
| Accuity | Evidently | |
|---|---|---|
| Pricing model | Contingency (pay from recoveries) · 60-day pilot, no upfront fees | Enterprise contract (custom) · Pricing not published |
| Speed to go live | Chart data feed plus 60-day pilot | SMART on FHIR pilot, then rollout |
| Automation model | Tech-enabled service · AI triage, physician-performed reviews | AI copilot · Surfaces evidence, humans decide |
| Built for | Enterprise systems | Mid-size groups, Enterprise systems |
| Security posture | HITRUST | SOC 2 Type II, HIPAA |
| Company maturity | 10 yrs (est. 2016) | 6 yrs (est. 2020) |
| Financial backing | Undisclosed | $15M · Series A |
| Named customers | 1 named | 3 named |
| Published results | Specific numbers public | No public numbers |
| Documented integrations | None documented | 4 listed |
| Third-party validation | None found | KLAS / analyst cited |
Bottom line
- Pick Accuity if you want guaranteed inpatient revenue capture from a physician-staffed service rather than another tool for your own team.
- Pick Evidently if you want one EHR-embedded chart intelligence layer serving clinicians, CDI, and risk adjustment together.
Accuity
Physician-led pre-bill chart review that recovers earned revenue
- Founded
- 2016
- HQ
- Mount Laurel, NJ
- Stage
- n/a
- Raised
- n/a
What it does
- Post-discharge, pre-bill second-level chart review
- Amplifi AI trained on 7M+ chart outcomes
- 185 multi-specialty physicians review flagged cases
- DRG, CC/MCC, and quality metric capture
- Medicaid expertise across 38 states
- Compliance oversight with 1.5% final denial rate
Where it's strong
- Runs after your CDI and coding teams finish, so it adds a safety net without changing their workflow.
- Scale is proven: 400+ hospital sites, 4 of the top 10 US health systems, and $3.3B in client revenue lift.
- Performance-based pricing with a 60-day pilot and no upfront fees keeps buyer risk low.
What buyers should weigh
- It is a service engagement, not software your team operates, so capability does not transfer in-house.
- Fees come out of recovered revenue, which costs more at scale than licensing a tool.
- Focused on inpatient pre-bill review; it does not address front-end or denial workflows.
Named customers
Temple Health
Evidently
EHR-embedded AI that turns scattered chart data into answers
- Founded
- 2020
- HQ
- San Francisco, CA
- Stage
- Series A
- Raised
- $15M
What it does
- AI chart summarization inside the EHR
- Ask Evidently chat pre-loaded with full chart
- CDI review and denial appeal support
- HCC capture and care gap reconciliation
- Note drafting for admits and discharges
- Registry abstraction and pre-op review
Where it's strong
- One chart-intelligence layer serves clinicians, CDI teams, and value-based care, spreading cost across use cases.
- Named academic and health system customers with third-party validation, including a 31.7-point Net EHR Experience Score gain at Iowa measured by KLAS.
- Allina Health documented 6x ROI on the value-based care use case.
What buyers should weigh
- Deep EHR embedding means IT involvement and a real pilot; UNC ran 12 weeks before enterprise rollout.
- It surfaces documentation and HCC opportunities but does not autonomously code or bill.
- At $15M raised it is a smaller vendor taking on well-funded CDI incumbents.
Named customers
University of Iowa Health Care · Allina Health · UNC Health
Integrations
Compare against the rest of Revenue Integrity & Pre-Bill Review
Deciding between these two?
First Pass tracks Revenue Integrity & Pre-Bill Review every week: funding, launches, and what changed since this page was written.